108 related articles for article (PubMed ID: 23235429)
1. [Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].
Khabirov FA; Babicheva NN; Khaĭbullin TI; Aver'ianova LA; Granatov EV; Akhmedova GM
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):113-22. PubMed ID: 23235429
[TBL] [Abstract][Full Text] [Related]
2. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
3. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
[TBL] [Abstract][Full Text] [Related]
4. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
6. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
Bayas A; Gold R
J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
[TBL] [Abstract][Full Text] [Related]
7. Betaferon in the treatment of multiple sclerosis.
Vidović M; Sinanović O; Burina A; Hudić J; Sehanović A
Acta Clin Croat; 2009 Sep; 48(4):419-21. PubMed ID: 20405637
[TBL] [Abstract][Full Text] [Related]
8. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
Bykova OV; Kuzenkova LM; Maslova OI
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
[TBL] [Abstract][Full Text] [Related]
9. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
Totolian NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):63-6. PubMed ID: 16117152
[No Abstract] [Full Text] [Related]
10. [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
Popova EV; Boyko AN; Bykova OV; Nankina IG; Batysheva TT
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):73-75. PubMed ID: 27456908
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
12. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
13. [The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis].
Boĭko AN; Batysheva TT; Bykova OV; Davydovskaia MV; Demina TL; Lashch NIu; Nankina IA; Ovcharov VV; Popova EV; Popova NF; Boĭko OV; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):98-103. PubMed ID: 22677685
[TBL] [Abstract][Full Text] [Related]
14. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
15. [Discontinuation and long-term adherence to beta interferon therapy in patients with multiple sclerosis].
Vicente Iturbe C; Ara Callizo JR; Huarte Lacunza R; Navarro Aznárez H; Serrano Mislata N; Rabanaque Hernández MJ
Farm Hosp; 2012; 36(2):77-83. PubMed ID: 21820930
[TBL] [Abstract][Full Text] [Related]
16. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis.
Wroe SJ
J Int Med Res; 2005; 33(3):309-18. PubMed ID: 15938592
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
18. Betaferon efficiency indicators in the treatment of relapsing remitting form of multiple sclerosis.
Suljic E; Sinanovic O; Kurtovic-Alajbegovic A; Klupka-Saric I
Med Arch; 2013; 67(3):178-80. PubMed ID: 23848037
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Sabanov AV; Luneva AV; Matveev NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963
[TBL] [Abstract][Full Text] [Related]
20. [Multiple sclerosis in the year 2000: advances in the treatment with interferon beta-1b].
Cendrowski W
Neurol Neurochir Pol; 2001; 35(5):855-65. PubMed ID: 11873598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
